2-PYRROLIDONE

ID: ALA276849

Max Phase: Preclinical

Molecular Formula: C4H7NO

Molecular Weight: 85.11

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (1): Pyrrolidin-2-one
Synonyms from Alternative Forms(1):

    Canonical SMILES:  O=C1CCCN1

    Standard InChI:  InChI=1S/C4H7NO/c6-4-2-1-3-5-4/h1-3H2,(H,5,6)

    Standard InChI Key:  HNJBEVLQSNELDL-UHFFFAOYSA-N

    Associated Targets(Human)

    Olfactory receptor 51E2 144 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Mus musculus 284745 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Rattus norvegicus 775804 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    GABA-A receptor; anion channel 5731 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Meloidogyne incognita 862 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: YesOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 85.11Molecular Weight (Monoisotopic): 85.0528AlogP: -0.10#Rotatable Bonds: 0
    Polar Surface Area: 29.10Molecular Species: NEUTRALHBA: 1HBD: 1
    #RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
    CX Acidic pKa: CX Basic pKa: CX LogP: -0.58CX LogD: -0.58
    Aromatic Rings: 0Heavy Atoms: 6QED Weighted: 0.44Np Likeness Score: 0.05

    References

    1. Li C, Schwartz EL, Mella SL, Rittmann LS, Sartorelli AC..  (1981)  Induction of differentiation of leukemia cells in vitro by N-substituted amides, lactams, and 2-pyridones.,  24  (9): [PMID:6945436] [10.1021/jm00141a016]
    2. Altomare C, Cellamare S, Carotti A, Casini G, Ferappi M, Gavuzzo E, Mazza F, Carrupt PT, Gaillard P, Testa B..  (1995)  X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore.,  38  (1): [PMID:7837228] [10.1021/jm00001a022]
    3. Reddy PA, Hsiang BC, Latifi TN, Hill MW, Woodward KE, Rothman SM, Ferrendelli JA, Covey DF..  (1996)  3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.,  39  (9): [PMID:8627613] [10.1021/jm9600196]
    4. Sykes NO, Macdonald SJ, Page MI..  (2002)  Acylating agents as enzyme inhibitors and understanding their reactivity for drug design.,  45  (13): [PMID:12061887] [10.1021/jm0111245]
    5. Imming P, Klar B, Dix D..  (2000)  Hydrolytic stability versus ring size in lactams: implications for the development of lactam antibiotics and other serine protease inhibitors.,  43  (22): [PMID:11063627] [10.1021/jm000921k]
    6. Kim YC, Zhao LX, Kim TH, Je SM, Kim EK, Choi H, Chae WG, Park M, Choi J, Jahng Y, Lee ES..  (2000)  Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.,  10  (7): [PMID:10762036] [10.1016/s0960-894x(00)00064-0]
    7. Sasaki H, Mori Y, Nakamura J, Shibasaki J..  (1991)  Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.,  34  (2): [PMID:1847429] [10.1021/jm00106a025]
    8. Caboni P, Sarais G, Aissani N, Tocco G, Sasanelli N, Liori B, Carta A, Angioni A..  (2012)  Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita.,  60  (30): [PMID:22769561] [10.1021/jf302075w]
    9. PubChem BioAssay data set, 
    10. PubChem BioAssay data set, 
    11.  (2018)  Modulators of Prostate-Specific G-Protein Receptor (PSGR/OR51E2) and Methods of Using Same,